Phase 1b randomized, controlled chemoprotection trial in patients with p53-mutated advanced non-small cell lung cancer who are receiving first-line platinum-based chemotherapy
Latest Information Update: 23 Feb 2023
At a glance
- Drugs ALRN 6924 (Primary) ; Carboplatin; Pemetrexed
- Indications Chemotherapy-induced damage
- Focus Registrational; Therapeutic Use
- 21 Feb 2023 According to an Aileron Therapeutics media release, based on the data from phase 1b breast cancer trial, company decided to terminate the further development of ALRN-6924.
- 21 Feb 2023 Status changed from recruiting to discontinued, according to an Aileron Therapeutics media release.
- 29 Jun 2022 According to an Aileron Therapeutics media release, the company will host a conference call and webcast to discuss results from this trial.